|
IMVT Immunovant Inc 1764013 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-505,606,000.00 |
| Balance Sheet |
|
Current Assets
|
$948,819,000.00 |
|
Assets
|
$957,014,000.00 |
|
Current Liabilities
|
$104,422,000.00 |
|
Liabilities
|
$104,422,000.00 |
|
Equity
|
$852,592,000.00 |
|
Shares Out
|
203940353.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-407,310,000.00 |
|
Investing Cash Flow
|
$-8,000.00 |
| Market Analysis |
Market Cap
|
$8,051,565,136.44 |
|
Price
|
$37.67 |
|
BVPS
|
4.18 |
|
PB
|
9.45 |
|
EPS
|
-2.77 |
|
FCF
|
$-407,318,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:17 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:12 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-06 |
-0.61 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-20 |
-0.73 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-11 |
-0.71 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-10 |
-0.73 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view IMVT documents filed with the SEC.
IMVT Filings
Clear
